Neural Stem Cells

Overview

Multipotent neural progenitors differentiated from UCT-WJ-MSCs; capable of differentiating into neurons, astrocytes, and oligodendrocytes with neurotrophic factor secretion

FOR RESEARCH USE AND INTERNATIONAL USE ONLY | Not for clinical use in the United States

Clinical potential

Akira Neural Stem Cells (NSCs) represent one of the most clinically significant differentiated products in the Akira portfolio. Generated from UCT-WJ-MSCs via neurosphere induction, these cells express the full NSC marker constellation and secrete a rich neurotrophic payload including BDNF, GDNF, NGF, CNTF, and VEGF. Their immune-privileged nature — inherited from the UCT-MSC parent — allows allogeneic use without immunosuppression, a critical advantage over ESC- or iPSC-derived neural cells. NSCs home to sites of neural injury via chemokine gradients (SDF-1/CXCR4) and integrate into existing neural circuits, modulating neuroinflammation and activating endogenous repair mechanisms. Multiple preclinical models confirm migration toward injury, reduction of lesion size, improvement in behavioral outcomes, and increased expression of synaptic plasticity markers.

Mechanism of Action

Neurogenic Differentiation: Under CNS microenvironmental cues, Akira NSCs differentiate into neurons (expressing β-III Tubulin, MAP2), astrocytes (GFAP+), and oligodendrocytes (MBP+). This direct cell replacement partially restores damaged circuits in TBI, spinal cord injury, and neurodegenerative models.

Neurotrophic Factor Secretion: NSCs constitutively secrete BDNF (brain-derived neurotrophic factor), GDNF (glial cell line-derived neurotrophic factor), NGF (nerve growth factor), and NT-3/NT-4. These factors bind Trk receptors on host neurons, promoting survival, axonal sprouting, synaptic strengthening, and inhibition of apoptosis.

Neuroinflammation Suppression: NSCs downregulate microglial M1 activation and shift microglia toward M2 repair phenotype via secretion of IL-10, TGF-β, and specialized pro-resolving mediators. Reduction of TNF-α, IL-1β, and IL-6 in the perilesional zone has been demonstrated in TBI and stroke models.

Remyelination Support: Oligodendrocyte-lineage derivatives of Akira NSCs produce myelin basic protein (MBP) and promote remyelination of demyelinated axons — directly relevant in MS and spinal cord injury.

Blood-Brain Barrier Preservation: NSC-derived exosomal cargo (miR-124, miR-132, miR-21) modulates tight junction protein expression (occludin, claudin-5, ZO-1), helping stabilize the BBB after injury.

Key Biomarkers & Molecular Cargo

Therapeutic Applications

• Alzheimer's Disease — neurotrophic support, synaptic preservation, amyloid clearance modulation
• Parkinson's Disease — dopaminergic circuit support, neuroprotection (use alongside Dopamine Neurocytes)
• Multiple Sclerosis — remyelination, neuroinflammation suppression
• Huntington's Disease — striatal neuron protection, neuroinflammation reduction
• ALS (Amyotrophic Lateral Sclerosis) — motor neuron survival extension
• Traumatic Brain Injury (TBI) — BBB stabilization, neurogenesis promotion, lesion size reduction
• Spinal Cord Injury (SCI) — axonal regeneration, functional motor recovery
• Stroke / Ischemic Brain Injury — neurogenesis, angiogenesis, inflammation control
• Autism Spectrum Disorder — neuroinflammation modulation, GABA/glutamate balance
• Cerebral Palsy — corticomotor pathway support
• Epilepsy (temporal lobe, refractory) — GABAergic neuron replacement, inflammation reduction
• Depression & Schizophrenia — hippocampal neurogenesis, dopamine/serotonin circuit modulation

Clinical & Preclinical Evidence

A 2019 study in Stem Cell Research & Therapy demonstrated that UCT-MSCs can be transdifferentiated into functional NSCs (neurospheres) within 12 hours using EGF bFGF. These MSC-derived neurospheres self-renewed, differentiated into neurons and glia, and showed significantly upregulated BDNF, GDNF, and VEGF secretion — a validated protocol underpinning Akira's NSC production.^[1]

A 2023 Phase I/IIa double-blind clinical trial (NEUROSTEM®) of UC-MSC intraventricular administration in mild-to-moderate Alzheimer's disease patients demonstrated acceptable safety and signals of cognitive stabilization on K-MMSE over 36 months post-administration. The trial utilized Ommaya reservoir delivery into the right lateral ventricle.^[2]

2023 research from Fudan University (published in CNS Neuroscience & Therapeutics) confirmed that hUC-MSC-derived exosomes attenuate neuroinflammation through the NRF2/NF-κB/NLRP3 pathway, reducing microglial activation and oxidative stress — with direct mechanistic relevance to NSC paracrine effects.^[3]

In spinal cord injury (SCI) rat models, UCT-MSC-derived exosomes inhibited NF-κB/MAPK signaling in microglia (BV2), reduced apoptosis, and suppressed inflammatory ROS production — demonstrating the broad anti-neuroinflammatory potency of this cell lineage's secretome.^[4]

A comprehensive 2023 review in Bioengineering covering MSC and NSC-derived exosomes in Alzheimer's disease synthesized 88 publications confirming that both MSC and NSC-derived vesicles reduce amyloid burden, tau phosphorylation, and neuroinflammatory markers in preclinical AD models.^[5] A 2023 systematic review of MSC-derived exosomes across clinical trials confirmed neurological indications among the most active therapeutic areas, with early-phase trials demonstrating consistent safety and biomarker-level efficacy signals.^[6]